Table 1

Characteristics at baseline of patients who did or did not develop AAA during 3 years of follow-up

Total patient population (n=99)AAA negative (n=44)‘Complexed AAA’ (n=26)AAA positive (n=29)
Demographics
 Age, mean (SD), year54 (11)53 (10)55 (12)54 (13)
 Sex, female, n (%)78 (79)33 (75)19 (73)26 (90)
Disease status
 Disease duration, median (IQR), year10 (5–17)8 (3–16)12 (5–23)12 (6–15)
 Rheumatoid factor positive, n (%)76 (77)34 (77)20 (77)22 (76)
 Anti-CCP positive, n (%)82 (83)37 (84)23 (89)28 (97)
 Erosive disease, n (%)80 (81)32 (73)22 (85)26 (90)
 ESR, median (IQR), mm/h22 (11–49)21 (9–42)22 (12–40)36 (12–68)
 C-reactive protein, median (IQR), mg/l14 (6–30)9 (4–20)†16 (8–22)22 (8–53)†
 DAS28, mean (SD)5.2 (1.4)4.9 (1.5)†5.0 (1.1)5.6 (1.3)†
(Co) medication
 Prior DMARDs, mean (SD)3.2 (1.3)3.1 (1.3)3.4 (1.3)3.2 (1.2)
 Prior biologicals, n (%)24 (24)7 (16)7 (27)10 (35)
 Methotrexate use, n (%)67 (68)39 (89)‡15 (58)*13 (45)†
 Methotrexate dose, median (IQR), mg/wk22.5 (15–25)25 (15–25)†22.5 (20–25)‡10 (7.5–22.5)† ‡
 Prednisone use, n (%)35 (35)14 (32)9 (35)12 (41)
 Prednisone dose, median (IQR), mg/day5 (5–10)5 (4–10)7.5 (5–10)7.5 (5–10)
  • *p=0.007 (Fisher's exact).

  • †CRP: p=0.006; DAS28: p=0.040; methotrexate use: p<0.001; methotrexate dose: p=0.006 (Mann–Whitney U, Fisher's exact, independent sample t test).

  • ‡p=0.012 (Mann–Whitney U).

  • AAA, anti-adalimumab antibodies; CCP, cyclic citrullinated peptide; DMARDs, disease-modifying anti-rheumatic drugs; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate.